10-Q: Hims & Hers Q1 2026: Revenue Up, But Profitability Declines

Hims & Hers Health, Inc. reported a 4% increase in total revenue for Q1 2026, reaching $608.1 million, but experienced a significant net loss of $92.1 million.

Summary

• Total revenue for the three months ended March 31, 2026, increased by 4% to $608.1 million, up from $586.0 million in the same period of 2025.
• United States revenue decreased by 8% to $529.9 million, while Rest of the World revenue surged by 969% to $78.2 million, largely due to recent acquisitions.
• The company reported a net loss of $92.1 million for the quarter, a significant decrease from a net income of $49.5 million in the prior year's quarter.
• Adjusted EBITDA decreased by 51% to $44.3 million from $91.1 million in the prior year's quarter.
• Subscribers increased by 9% to approximately 2.6 million.
• Monthly Revenue per Average Subscriber decreased by 6% to $80.
• The company incurred $33.5 million in restructuring and other related charges, primarily related to its US weight loss offering strategy shift.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, decrease in Adjusted EBITDA, and declining gross margins, despite modest revenue growth and subscriber increase. The increased operating expenses and restructuring charges also contribute to a cautious outlook.

Positives

• Total revenue increased by 4% to $608.1 million.
• Rest of the World revenue saw substantial growth of 969% to $78.2 million, driven by acquisitions.
• Subscriber base grew by 9% to 2.6 million.
• Free Cash Flow increased to $53.0 million from $50.1 million in the prior year.

Negatives

• Net loss widened significantly to $92.1 million from a net income of $49.5 million in the prior year.
• Adjusted EBITDA decreased by 51% to $44.3 million.
• Gross profit decreased by 8% to $396.8 million, with gross margin declining to 65% from 73%.
• Monthly Revenue per Average Subscriber decreased by 6% to $80.
• Marketing expenses decreased by 4% to $222.0 million, but operations and support, technology and development, and general and administrative expenses all increased significantly.
• General and administrative expenses more than doubled, increasing by 126% to $109.7 million.

Risks

• The company faces risks related to the evolving regulatory landscape for compounded GLP-1s, with the FDA and HHS taking actions that could require significant resources and potentially lead to reputational harm or operational disruptions.
• A strategic shift in the US weight loss offering and the launch of a membership program introduce risks related to customer acquisition, pricing, and retention, with potential for increased churn or reduced engagement.
• Reliance on third-party manufacturers and supply chains for branded GLP-1 products exposes the company to potential supply disruptions and pricing changes.
• The company is subject to extensive regulation in the healthcare and pharmacy industries, and failure to comply with applicable laws could result in substantial penalties.
• The company faces potential liability from product liability claims, and its insurance coverage may not be sufficient.
• Security breaches, loss of data, and other disruptions could compromise sensitive information and expose the company to liability.
• The company's dual-class stock structure concentrates voting power, limiting investor influence.
• The proposed acquisition of Eucalyptus is subject to closing conditions, and any delay or failure to complete the acquisition could adversely affect the business.
• The company may require additional capital, and there is no guarantee it will be available on acceptable terms.

Future Outlook

The company expects to continue investing in growth, including fulfillment, operating capabilities, marketing, product offerings, and customer experience. Expansion into new health and wellness specialties is also anticipated. However, the company acknowledges that investments in growth may increase operating expenses in the short term. The company believes its existing cash resources and availability under its revolving credit facility are sufficient to support planned operations for the next 12 months.

Management Comments

• The company's mission is to help the world feel great through the power of better health.
• We believe that we have the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format.
• We expect our gross margin to fluctuate from period to period depending on various factors, but over the long term, we expect gross margin to stabilize as we continue to scale our business and increase our ability to negotiate and optimize more favorable costs of revenue, as well as integrate new acquisitions.
• Marketing is an important driver of growth and we intend to continue to make significant investments in customer acquisition and our marketing organization.
• We expect technology and development expenses may increase in the foreseeable future as we grow our business and continue to invest in our platform, including our artificial intelligence capabilities, as well as in new offerings.

Industry Context

StockSavvy.ai notes that Hims & Hers is operating in the rapidly growing digital health and telehealth sector. The company's strategic shift in its US weight loss offering and expansion into international markets through acquisitions are key trends impacting the industry. The increased scrutiny on compounded GLP-1s by regulatory bodies like the FDA and HHS reflects a broader industry trend of heightened regulatory oversight in the digital health space.

Comparison to Industry Standards

• The company's revenue growth of 4% is modest compared to some high-growth digital health companies, but its international expansion through acquisitions is a common strategy for market penetration and diversification.
• The decline in gross margin from 73% to 65% is a concern, especially when compared to industry benchmarks where maintaining healthy gross margins is crucial for sustainable profitability. This decline is attributed to factors like shorter shipping cadences and the impact of the US weight loss offering strategy shift.
• The significant increase in operating expenses, particularly in General and Administrative (up 126%), suggests substantial investment in integration, compliance, and scaling, which is typical for companies undergoing rapid expansion and acquisitions, but needs to be monitored for efficiency.
• The decrease in Monthly Revenue per Average Subscriber, while potentially influenced by shipping cadence changes, warrants attention as customer value realization is key in subscription models. Industry best practices focus on increasing ARPU (Average Revenue Per User) through value-added services or optimized product mix.

Legal Proceedings

• The company is responding to a Civil Investigative Demand from the FTC regarding privacy, advertising, and cancellation practices, with active settlement negotiations underway. An accrual of $15.0 million has been made for potential losses.
• Two putative securities class action lawsuits have been consolidated, alleging violations of securities laws in connection with misrepresentations regarding the company's business, operations, and prospects, particularly concerning its relationship with Novo Nordisk.
• Putative shareholder derivative lawsuits have been filed against certain directors and executives, related to the matters alleged in the securities actions, alleging breaches of fiduciary duty.
• Novo Nordisk A/S filed a patent infringement lawsuit related to compounded GLP-1 products containing semaglutide, but voluntarily dismissed all claims without prejudice.

Related Party Transactions

• For the three months ended March 31, 2025, the company recorded $1.4 million for payments made to Woolly Labs, Inc. (d/b/a Vouched) for identity verification services. Vouched was no longer considered a related party as of July 1, 2025, due to an executive leadership change.

Stakeholder Impact

• Shareholders may be concerned by the significant net loss and decrease in Adjusted EBITDA, potentially impacting stock price volatility.
• Customers may experience changes in service offerings and pricing due to the strategic shift in the US weight loss business and the introduction of a membership program.
• Employees may be affected by the company's growth investments and potential restructuring, though specific impacts are not detailed.
• Suppliers and partners may face evolving business relationships due to acquisitions and strategic shifts, particularly concerning supply chain for GLP-1 products.

Next Steps

• Continue to invest in fulfillment, distribution, and operating capabilities.
• Invest in marketing to acquire new customers across all brands.
• Continue to invest in product offerings and customer experience.
• Pursue opportunities to acquire or invest in complementary businesses, services, and technologies.
• Monitor and adapt to evolving regulatory requirements, particularly concerning compounded GLP-1s and digital health services.
• Evaluate the impact of the strategic shift in the US weight loss offering and the new membership program.

Key Dates

Recommendation

The company's Q1 2026 results show a significant deterioration in profitability, with a substantial net loss and a sharp decline in Adjusted EBITDA, contrasting with the prior year's profitability. While revenue and subscriber growth are positive, the increased operating expenses, particularly in G&A, and the declining gross margins indicate significant cost pressures and potential integration challenges from recent acquisitions. The regulatory scrutiny surrounding compounded GLP-1s adds a layer of uncertainty. Given these factors, a cautious approach is warranted, suggesting a sell or hold recommendation until profitability and cost management improve.

Keywords

Hims & Hers, Form 10-Q, Quarterly Report, Financial Results, Revenue, Net Loss, Adjusted EBITDA, Subscribers, Telehealth, Weight Loss, GLP-1